淋巴毒素β受体融合蛋白巴米西普治疗原发性干燥综合征的临床疗效与安全性:一项II期随机双盲安慰剂对照试验结果
这项多中心II期随机双盲安慰剂对照试验将52例原发性干燥综合征患者按2:1随机分配,每周皮下注射100 mg巴米西普或安慰剂,共24周。主要终点刺激全唾液流率变化在两组间无显著差异(基线校正均值变化-0.01 vs 0.07 ml/分钟;P=0.332),ESSDAI变化亦无显著差异(-1.23 vs -0.15;P=0.104)。巴米西普治疗与肝毒性发生率较高相关,包括2例严重不良事件。
要点
- 巴米西普未能显著改善原发性干燥综合征的腺体和腺外疾病。
- 刺激全唾液流率变化两组无显著差异(-0.01 vs 0.07 ml/分钟;P=0.332)。
- 巴米西普治疗与肝毒性发生率较高相关,包括2例严重不良事件。
核心结论
- 巴米西普治疗未能显著改善原发性干燥综合征患者的腺体和腺外疾病,尽管机制研究显示其阻断LTβR信号通路。
研究设计与样本
- 多中心II期随机双盲安慰剂对照试验,52例原发性干燥综合征患者按2:1随机分配接受每周皮下注射100 mg巴米西普或匹配安慰剂,共24周。
主要发现
- 刺激全唾液流率从基线至第24周的变化在巴米西普组与安慰剂组间无显著差异(基线校正均值变化-0.01 vs 0.07 ml/分钟;P=0.332)。
- ESSDAI在治疗期间的变化在两组间亦无显著差异(基线校正均值变化-1.23 vs -0.15;P=0.104)。
- 不良事件发生率在两组间相似,但巴米西普治疗与肝毒性发生率较高相关,包括2例严重不良事件。
- 巴米西普显著降低血浆CXCL13水平,并显著改变循环B细胞和T细胞数量,与其已知的LTβR信号抑制效应一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the clinical efficacy and safety of baminercept, a lymphotoxin β receptor IgG fusion protein (LTβR-Ig), for the treatment of primary Sjögren's syndrome (SS), and to explore the possible mechanisms of action of this treatment. METHODS: In this multicenter trial, 52 patients with primary SS were randomized in a 2:1 ratio to receive subcutaneous injections of 100 mg of baminercept every week for 24 weeks or matching placebo. The primary end point was the change between screening and week 24 in the stimulated whole salivary flow (SWSF) rate. Secondary end points included the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI), as well as measurements of select chemokines and cytokines and enumeration of peripheral blood B and T cell subsets. RESULTS: The change from baseline to week 24 in the SWSF rate was not significantly different between the baminercept and placebo treatment groups (baseline-adjusted mean change -0.01 versus 0.07 ml/minute; P = 0.332). The change in the ESSDAI during treatment was also not significantly different between the treatment groups (baseline-adjusted mean change -1.23 versus -0.15; P = 0.104). Although the incidence of adverse events was similar between the treatment groups, baminercept therapy was associated with a higher incidence of liver toxicity, including 2 serious adverse events. Baminercept also produced a significant decrease in plasma levels of CXCL13 and significant changes in the number of circulating B and T cells, consistent with its known inhibitory effects on LTβR signaling. CONCLUSION: In this trial, treatment with baminercept failed to significantly improve glandular and extraglandular disease in patients with primary SS, despite evidence from mechanistic studies showing that it blocks LTβR signaling.
引用
- St Clair EW, Baer AN, Wei C, et al. Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2018. PMID: 29604186. doi:10.1002/art.40513
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。